Unicycive Therapeutics Reports Strong Cash Position and FDA Acceptance for OLC NDA Resubmission

summarizeSummary

Unicycive Therapeutics announced full year 2025 financial results with a reduced net loss, a strong cash position of $54.9 million providing runway into 2027, and FDA acceptance of its OLC NDA resubmission with a PDUFA date of June 29, 2026.

check_boxKey Events

• FDA Accepts OLC NDA Resubmission

  The FDA accepted the New Drug Application (NDA) resubmission for oxylanthanum carbonate (OLC), an investigational oral phosphate binder, setting a PDUFA target action date of June 29, 2026. This advances the lead product towards potential commercialization.

• Strong Cash Position and Extended Runway

  As of March 30, 2026, the company reported unaudited cash, cash equivalents, and marketable securities totaling $54.9 million, which is expected to fund operations into 2027. This provides significant financial stability for a clinical-stage biotech.

• Reduced Net Loss in FY2025

  For the full year ended December 31, 2025, Unicycive Therapeutics reported a net loss of $26.6 million, a notable decrease from the $37.8 million loss in the prior year, reflecting improved financial performance.

• Commercial Readiness Underway

  The company is continuing to strengthen its commercial infrastructure and advance market readiness initiatives in anticipation of a potential launch of OLC in Q3 2026, if approved.

auto_awesomeAnalysis

This 8-K details Unicycive Therapeutics' full year 2025 financial results and provides a critical business update. The company reported a significantly reduced net loss and a robust cash position of $54.9 million, extending its operational runway into 2027. This financial stability is crucial for a clinical-stage biotechnology company. Furthermore, the FDA's acceptance of the OLC NDA resubmission with a PDUFA date of June 29, 2026, marks a significant step towards potential commercialization of its lead product for hyperphosphatemia. The positive regulatory progress, combined with a strong balance sheet, de-risks the company's near-term outlook and supports its commercial readiness activities.